Second-line treatments for advanced thyroid cancer
This study looks at the effectiveness of different targeted therapy medications for people with advanced thyroid cancer that is no longer responding to standard treatment. It may help doctors understand which treatment options work best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with thyroid cancer
- You have a specific type called differentiated thyroid cancer
- You have started a targeted therapy medication (like lenvatinib, sorafenib, or similar) or a combination therapy since January 2019
- You have not had surgery to cure the cancer within 3 months of starting that treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called 177Lu-LNC1004 for people with a type of thyroid cancer that is no longer responding to standard treatments. The drug targets a protein called FAP found on tumor cells, which may help shrink tumors and slow disease progression.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
This study tests a new combination of targeted drugs (dabrafenib and trametinib) compared to chemotherapy (cabozantinib) for people with a specific type of advanced thyroid cancer called BRAF-mutated differentiated thyroid cancer. The goal is to see which treatment works better.
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
This trial tests whether giving targeted drugs before surgery can shrink advanced thyroid cancers that are hard to remove. It uses genetic test results to match you to a specific treatment arm, aiming to make surgery safer and more successful.
Hear when a new Radioiodine-refractory Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.